publication date: May. 4, 2018

CTEP Protocols

NCI Trials for May

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase 1 – 10187

A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma

National Heart Lung and Blood Institute
Childs, Richard W.
(301) 451-7128


Phase II – EA9171

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

ECOG-ACRIN Cancer Research Group
Zeidan, Amer M.
(203) 737-2572


Phase II – NRG-GU006

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer

NRG Oncology
Feng, Felix Yi-Chung
(415) 353-7183


Phase III – CCTG MA.39

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Canadian Cancer Trials Group
Whelan, Timothy Joseph
(905) 387-9711


Phase Other – ANBL17B5-Q

Growth Factor Receptor Trafficking and Neuroblastoma Differentiation

Children’s Oncology Group
Zage, Peter Eric
(858) 534-6494

Copyright (c) 2020 The Cancer Letter Inc.